FIELD: biotechnology.
SUBSTANCE: invention relates to methods for determining expression of signature genes for diagnosis of patients with prostate cancer, for example to determine a prediction for such patients, to determine predisposition of said patient to development of aggressive or indolent disease, for example, after primary therapy and/or for identification and stratification of patients on available methods of treatment. Invention also relates to products used in such methods, for example, sets and software. Besides, the present invention refers to types of therapy for use in treating patients, which have been diagnosed, identified or stratified in any of the methods described herein.
EFFECT: there are presented methods for prediction of prostate cancer.
12 cl, 13 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RISK ASSESSMENT BASED ON EXPRESSION OF HUMAN 4D PHOSPHODIESTERASE OPTION 7 | 2017 |
|
RU2766885C2 |
| PREOPERATIVE RISK STRATIFICATION BASED ON PDE4D7 AND DHX9 EXPRESSION | 2019 |
|
RU2793635C2 |
| HUMANIZED ANTI-PSMA ANTIBODIES | 2019 |
|
RU2794450C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| HERPES SIMPLEX SYNCYTIAL ONCOLYTIC MUTANTS AS POWERFUL THERAPEUTIC AGENTS FOR TREATING CANCER | 2020 |
|
RU2821999C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
